As Australian shares enter their seventh consecutive day in the red, market sentiment has shifted into bearish territory amid concerns over rising inflation and potential interest rate hikes. In this challenging environment, growth companies with high insider ownership can be appealing as they often indicate strong confidence from those who know the business best.

Top 10 Growth Companies With High Insider Ownership In Australia

Name Insider Ownership Earnings Growth Torque Metals (ASX:TOR) 18.3% 94.2% Starpharma Holdings (ASX:SPL) 15.6% 91.8% SKS Technologies Group (ASX:SKS) 28.2% 31.7% Magnetic Resources (ASX:MAU) 33.6% 124.2% Forrestania Resources (ASX:FRS) 32.4% 102.3% Elsight (ASX:ELS) 12.6% 51.4% Echo IQ (ASX:EIQ) 19.7% 108.7% Austral Resources Australia (ASX:AR1) 19.4% 38.8% Adveritas (ASX:AV1) 17.9% 109.9% Advanced Energy Minerals (ASX:AEM) 37.5% 48.4%

Click here to see the full list of 111 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Let's review some notable picks from our screened stocks.

Artrya

Simply Wall St Growth Rating: ★★★★★☆

Overview: Artrya Limited is a medical technology company focused on developing and commercializing an artificial intelligence platform for detecting, diagnosing, and addressing coronary artery disease in Australia, with a market cap of A$658.37 million.

Operations: Artrya Limited generates revenue from the development of its AI-driven CCTA image analysis technology, amounting to A$0.03 million.

Insider Ownership: 13.5%

Revenue Growth Forecast: 61.9% p.a.

Artrya, recently added to the S&P/ASX All Ordinaries and Emerging Companies Indexes, showcases high growth potential with revenue expected to grow at 61.9% annually, outpacing the Australian market. Despite a current net loss of A$10.74 million for the half year ending December 2025, forecasts suggest profitability within three years. The company has seen significant executive changes and remains undervalued by approximately 87.9% against fair value estimates, indicating potential upside for investors focused on growth opportunities with strong insider involvement.

Navigate through the intricacies of Artrya with our comprehensive analyst estimates report here. In light of our recent valuation report, it seems possible that Artrya is trading behind its estimated value.ASX:AYA Ownership Breakdown as at Apr 2026

IperionX

Simply Wall St Growth Rating: ★★★★★☆

Overview: IperionX Limited focuses on developing mineral properties in the United States and has a market capitalization of A$1.42 billion.

Operations: IperionX Limited does not currently have any revenue segments to report.

Story Continues

Insider Ownership: 17.2%

Revenue Growth Forecast: 61.6% p.a.

IperionX is positioned for substantial growth, with revenue expected to increase by 61.6% annually, surpassing the Australian market average. Despite a recent net loss of US$34.77 million for the half-year ending December 2025, profitability is anticipated within three years. The company has experienced significant insider selling recently but maintains high insider ownership levels. Recent executive changes include appointing Louisa Martino as Company Secretary, enhancing corporate governance and strategic oversight capabilities.

Unlock comprehensive insights into our analysis of IperionX stock in this growth report. Our valuation report here indicates IperionX may be overvalued.ASX:IPX Earnings and Revenue Growth as at Apr 2026

Mesoblast

Simply Wall St Growth Rating: ★★★★★★

Overview: Mesoblast Limited develops regenerative medicine products across Australia, the United States, Singapore, and Switzerland, with a market capitalization of A$2.88 billion.

Operations: The company's revenue is primarily generated from the development of a cell technology platform for commercialization, amounting to $65.38 million.

Insider Ownership: 34.9%

Revenue Growth Forecast: 45.1% p.a.

Mesoblast is poised for significant growth, with forecasted revenue expansion of 45.1% annually, outpacing the Australian market. The company has seen substantial insider buying over the past three months, signaling confidence in its prospects. Recent developments include a pivotal Phase 3 trial for rexlemestrocel-L targeting chronic low back pain and FDA clearance for Ryoncil's trial in Duchenne muscular dystrophy. Despite historical losses, profitability is expected within three years, supported by robust product pipelines and strategic clinical advancements.

Get an in-depth perspective on Mesoblast's performance by reading our analyst estimates report here. According our valuation report, there's an indication that Mesoblast's share price might be on the expensive side.ASX:MSB Ownership Breakdown as at Apr 2026

Turning Ideas Into Actions

Explore the 111 names from our Fast Growing ASX Companies With High Insider Ownership screener here. Looking For Alternative Opportunities? We've found 16 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include ASX:AYA ASX:IPX and ASX:MSB.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments